BCAT1 and chronic myelogenous leukemia, BCR-ABL1 positive: At the variance with the observations made in AMLs, in CML BCAT1 has been shown to increase cellular concentrations of BCAAs to stimulate mTOR activity, to drive protein synthesis, growth and survival [162].